Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer

Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

(2011) Peter S. Hammerman et al.   Cancer Discovery

Amplification of chromosomal segment 4q12 in non-small cell lung cancer

(2010) Alex H. Ramos et al.   CANCER BIOLOGY & THERAPY

FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer

(2010) N. Turner et al.   CANCER RESEARCH

A Structure-Guided Approach to Creating Covalent FGFR Inhibitors

(2010) Wenjun Zhou et al.   CHEMISTRY & BIOLOGY

Exciting New Targets in Lung Cancer Therapy: ALK, IGF-1R, HDAC, and Hh

(2010) Joel W. Neal et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer

(2010) Alberto Bardelli et al.   JOURNAL OF CLINICAL ONCOLOGY

The landscape of somatic copy-number alteration across human cancers

(2010) Rameen Beroukhim et al.   NATURE

Integrative Genomic Analyses Identify BRF2 as a Novel Lineage-Specific Oncogene in Lung Squamous Cell Carcinoma

(2010) William W. Lockwood et al.   PLOS MEDICINE

Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines

(2009) Y. Kataoka et al.   ANNALS OF ONCOLOGY

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-  Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase Inhibitors

(2009) U. McDermott et al.   CANCER RESEARCH

Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: An approach to identify candidate genes involved in tumor development

(2009) Edoardo Missiaglia et al.   GENES CHROMOSOMES & CANCER

Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions

(2009) Martin L. Sos et al.   JOURNAL OF CLINICAL INVESTIGATION

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas

(2009) Adam J Bass et al.   NATURE GENETICS

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

(2009) Rafael Rosell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine

(2009) J. S. Ross et al.   ONCOLOGIST

BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy

(2008) F. Hilberg et al.   CANCER RESEARCH

A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

(2008) D. Sarker et al.   CLINICAL CANCER RESEARCH

Drug-sensitive FGFR2 mutations in endometrial carcinoma

(2008) A. Dutt et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA